Celgene joined investors including Alexandria Venture Investments to expand the cell therapy developer's series B round by an extra $11m.

Existing backer Otsuka Holdings has agreed to acquire the remaining shares in portfolio company Recor, the creator of a device that treats hypertension.

Hebrew University of Jerusalem has spun out NewStem to develop a stem cell-based approach for predicting whether a cancer patient is likely to respond to chemotherapy.

The robotic exoskeleton producer has raised an initial $81.9m for the fund, which has secured several corporate LPs.

Spun out of University of Cape Town, Nisonic hopes to use ultrasound to provide a better method for tracking brain pressure to monitor conditions such as stroke, brain tumours and head trauma.

Alexandria Venture Investments and Biomed Realty Ventures were among the investors as the immunotherapy developer closed the round's final tranche.

SMK Diagnostics is developing a sensor that can detect mosquito-borne diseases more quickly and cheaply than alternative methods.